Amgen to Offer $4 Billion in Three Series of Senior Notes; Company to Purchase Approximately $3 Billion in Common Stock Read more about Amgen to Offer $4 Billion in Three Series of Senior Notes; Company to Purchase Approximately $3 Billion in Common Stock
Amgen Names David Lacey, M.D., Senior Vice President, Head of Research Read more about Amgen Names David Lacey, M.D., Senior Vice President, Head of Research
Amgen Recommends Rejection of Mini-Tender Offer by TRC Capital Corporation Read more about Amgen Recommends Rejection of Mini-Tender Offer by TRC Capital Corporation
Amgen Announces Voting Results of Annual Meeting of Stockholders Read more about Amgen Announces Voting Results of Annual Meeting of Stockholders
Final Vectibix(TM) Positive Pivotal Phase 3 Trial Results In Metastatic Colorectal Cancer Patients Published Read more about Final Vectibix(TM) Positive Pivotal Phase 3 Trial Results In Metastatic Colorectal Cancer Patients Published
Amgen's First Quarter 2007 Revenue Increased 15 Percent to $3.7 Billion Read more about Amgen's First Quarter 2007 Revenue Increased 15 Percent to $3.7 Billion
Aranesp(R) ``145 Study'' Shows No Difference in Survival in Patients with Small-Cell Lung Cancer Read more about Aranesp(R) ``145 Study'' Shows No Difference in Survival in Patients with Small-Cell Lung Cancer
2007 Recipients of Amgen Award for Science Teaching Excellence Announced Read more about 2007 Recipients of Amgen Award for Science Teaching Excellence Announced
Aranesp(R) Phase 3 Study in Patients with Active Cancer Not Receiving Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual Meeting Read more about Aranesp(R) Phase 3 Study in Patients with Active Cancer Not Receiving Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual Meeting
Amgen Announces Webcast of 2007 First Quarter Financial Results Read more about Amgen Announces Webcast of 2007 First Quarter Financial Results
